Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNYSE:PBHNASDAQ:PCRXNASDAQ:PRNBNASDAQ:TPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$8.47-2.0%$8.09$5.20▼$10.67$1.14B1.151.35 million shs2.12 million shsPBHPrestige Consumer Healthcare$79.84-1.3%$84.14$64.94▼$90.04$3.95B0.45302,956 shs386,979 shsPCRXPacira BioSciences$23.90+1.8%$25.40$11.16▼$29.33$1.11B0.52952,350 shs1.06 million shsPRNBPrincipia Biopharma$100.05$100.05$25.35▼$101.89$3.32B0.86729,676 shsN/ATPTXTurning Point Therapeutics$76.01$75.83$23.77▼$82.20$3.81B-0.181.14 million shs4,322 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals0.00%+11.20%+9.92%+7.46%+51.31%PBHPrestige Consumer Healthcare0.00%-2.85%-5.57%-5.89%+17.65%PCRXPacira BioSciences0.00%-3.10%-8.96%-5.51%-17.93%PRNBPrincipia Biopharma0.00%0.00%0.00%0.00%0.00%TPTXTurning Point Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals2.5144 of 5 stars3.51.00.00.02.00.81.9PBHPrestige Consumer Healthcare4.1802 of 5 stars2.34.00.03.53.01.71.9PCRXPacira BioSciences3.4894 of 5 stars2.22.00.03.92.72.50.6PRNBPrincipia BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ATPTXTurning Point TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5035.77% UpsidePBHPrestige Consumer Healthcare 2.50Moderate Buy$93.3316.90% UpsidePCRXPacira BioSciences 2.33Hold$26.4410.65% UpsidePRNBPrincipia Biopharma 0.00N/AN/AN/ATPTXTurning Point Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PBH, PRNB, AUPH, PCRX, and TPTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025PCRXPacira BioSciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $30.005/8/2025PBHPrestige Consumer HealthcareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/8/2025PCRXPacira BioSciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/8/2025PCRXPacira BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$48.00 ➝ $65.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$235.13M4.87$0.30 per share28.01$2.68 per share3.16PBHPrestige Consumer Healthcare$1.14B3.47$5.14 per share15.52$37.04 per share2.16PCRXPacira BioSciences$702.77M1.57$4.39 per share5.44$16.86 per share1.42PRNBPrincipia Biopharma$35.16M94.50N/AN/A$10.95 per share9.14TPTXTurning Point Therapeutics$30.83M123.46N/AN/A$15.84 per share4.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$5.75M$0.2830.2515.13N/A16.11%14.27%9.93%7/30/2025 (Estimated)PBHPrestige Consumer Healthcare$214.60M$4.2918.6116.772.4318.86%12.87%6.78%8/6/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.28N/A9.30N/A-14.78%13.78%7.00%7/29/2025 (Estimated)PRNBPrincipia Biopharma-$53.79M-$2.09N/AN/AN/AN/A-23.08%-21.11%N/ATPTXTurning Point Therapeutics-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/ALatest PBH, PRNB, AUPH, PCRX, and TPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/APBHPrestige Consumer HealthcareN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AN/ATPTXTurning Point TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.165.935.26PBHPrestige Consumer Healthcare0.554.202.82PCRXPacira BioSciences0.482.411.99PRNBPrincipia BiopharmaN/A17.0117.01TPTXTurning Point TherapeuticsN/A16.8316.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%PBHPrestige Consumer Healthcare99.95%PCRXPacira BioSciences99.73%PRNBPrincipia Biopharma95.54%TPTXTurning Point Therapeutics90.33%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%PBHPrestige Consumer Healthcare1.60%PCRXPacira BioSciences6.40%PRNBPrincipia Biopharma16.01%TPTXTurning Point Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million118.62 millionOptionablePBHPrestige Consumer Healthcare54049.42 million48.62 millionOptionablePCRXPacira BioSciences72046.29 million43.33 millionOptionablePRNBPrincipia Biopharma6533.21 millionN/ANot OptionableTPTXTurning Point Therapeutics25050.07 million45.77 millionNot OptionablePBH, PRNB, AUPH, PCRX, and TPTX HeadlinesRecent News About These CompaniesTurning Point Therapeutics Inc (TPTX) - Investing.comJune 26, 2025 | investing.comBMS sets up Roche, Pfizer rivalry with Turning Point takeoverMay 20, 2025 | pharmaphorum.comPDigging Into Turning Point USA’s Role in the Trump 2024 Ground GameOctober 8, 2024 | talkingpointsmemo.comTTurning Point of Tampa Now In-Network with Blue Cross Blue Shield InsuranceSeptember 29, 2024 | markets.businessinsider.comDigital therapeutics at a turning point: What we heard at DTx EastSeptember 14, 2024 | pharmaphorum.comPPTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comTG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | seekingalpha.comViking Therapeutics, Inc. (VKTX) Q2 2024 Earnings Call TranscriptJuly 25, 2024 | seekingalpha.comGlass System in Turning Point ResidenceApril 2, 2024 | archdaily.comABid to remove prosecutors sets up turning point in Trump’s Georgia caseFebruary 19, 2024 | politico.comPTurning Point Brands Inc.February 17, 2024 | wsj.comAlzheimer’s: A Turning Point?February 12, 2024 | bbc.co.ukTurning Point Brands Inc (TPB)February 10, 2024 | investing.comCormorant Asset Management, LP's Net WorthFebruary 10, 2024 | benzinga.comSolving quadratic equations - EdexcelJanuary 15, 2024 | bbc.co.ukCOP15: A Turning Point for Investor Approaches to BiodiversityDecember 19, 2023 | morningstar.comMTurning Point USA: Are conservatives fighting back on campus?December 16, 2023 | bbc.comBBMS bet looking good as Augtyro approved in ROS1-positive NSCLCNovember 16, 2023 | thepharmaletter.comTPhD Study : Developing an AI-enabled point-of-care monitoring system to detect systemic concentration of therapeutics in bloodOctober 29, 2023 | ulster.ac.ukUA Turning Point for Japan-US Climate Cooperation?October 28, 2023 | thediplomat.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBH, PRNB, AUPH, PCRX, and TPTX Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$8.47 -0.17 (-1.97%) As of 04:00 PM EasternAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Prestige Consumer Healthcare NYSE:PBH$79.84 -1.06 (-1.31%) As of 03:58 PM EasternPrestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.Pacira BioSciences NASDAQ:PCRX$23.90 +0.42 (+1.79%) As of 04:00 PM EasternPacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.Principia Biopharma NASDAQ:PRNBPrincipia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.Turning Point Therapeutics NASDAQ:TPTXTurning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
